Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · IEX Real-Time Price · USD
22.50
+1.10 (5.14%)
At close: May 1, 2024, 4:00 PM
23.24
+0.74 (3.29%)
Pre-market: May 2, 2024, 4:31 AM EDT
Intellia Therapeutics Revenue
In the year 2023, Intellia Therapeutics had annual revenue of $36.28M, a decrease of -30.40%. Revenue in the quarter ending December 31, 2023 was $-1.92M, a -114.12% decrease year-over-year.
Revenue (ttm)
$36.28M
Revenue Growth
-30.40%
P/S Ratio
59.82
Revenue / Employee
$68,964
Employees
526
Market Cap
2.17B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 36.28M | -15.85M | -30.40% |
Dec 31, 2022 | 52.12M | 19.07M | 57.69% |
Dec 31, 2021 | 33.05M | -24.94M | -43.01% |
Dec 31, 2020 | 57.99M | 14.89M | 34.55% |
Dec 31, 2019 | 43.10M | 12.67M | 41.63% |
Dec 31, 2018 | 30.43M | 4.32M | 16.53% |
Dec 31, 2017 | 26.12M | 9.64M | 58.49% |
Dec 31, 2016 | 16.48M | 10.44M | 172.65% |
Dec 31, 2015 | 6.04M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Teladoc Health | 2.62B |
CONMED | 1.26B |
Amphastar Pharmaceuticals | 644.40M |
Inari Medical | 493.63M |
TG Therapeutics | 233.66M |
Deciphera Pharmaceuticals | 163.36M |
Kymera Therapeutics | 78.59M |
Keros Therapeutics | 151.00K |
NTLA News
- 2 days ago - Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024 - GlobeNewsWire
- 6 weeks ago - Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy - GlobeNewsWire
- 2 months ago - Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress - GlobeNewsWire
- 2 months ago - Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis - Business Wire
- 2 months ago - Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates - GlobeNewsWire
- 3 months ago - Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine - GlobeNewsWire
- 3 months ago - SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa - GlobeNewsWire
- 4 months ago - Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones - GlobeNewsWire